169 related articles for article (PubMed ID: 38424666)
1. Editorial Comment to Real-world sequential treatment patterns and clinical outcomes among patients with advanced urothelial carcinoma in Japan.
Kondo T
Int J Urol; 2024 May; 31(5):560-561. PubMed ID: 38424666
[No Abstract] [Full Text] [Related]
2. Editorial Comment on Real-world sequential treatment patterns and clinical outcomes among patients with advanced urothelial carcinoma in Japan.
Ishihara H; Takagi T
Int J Urol; 2024 May; 31(5):559-560. PubMed ID: 38366784
[No Abstract] [Full Text] [Related]
3. A new standard of care for advanced-stage urothelial carcinoma.
Sidaway P
Nat Rev Clin Oncol; 2024 May; 21(5):336. PubMed ID: 38509334
[No Abstract] [Full Text] [Related]
4. Real-world sequential treatment patterns and clinical outcomes among patients with advanced urothelial carcinoma in Japan.
Kita Y; Otsuka H; Ito K; Hara T; Shimura S; Kawahara T; Kato M; Kanamaru S; Inoue K; Ito H; Igarashi A; Sazuka T; Takamatsu D; Hashimoto K; Abe T; Naito S; Matsui Y; Nishiyama H; Kitamura H; Kobayashi T;
Int J Urol; 2024 May; 31(5):552-559. PubMed ID: 38303567
[TBL] [Abstract][Full Text] [Related]
5. ESMO Clinical Practice Guideline interim update on first-line therapy in advanced urothelial carcinoma.
Powles T; Bellmunt J; Comperat E; De Santis M; Huddart R; Loriot Y; Necchi A; Valderrama BP; Ravaud A; Shariat SF; Szabados B; van der Heijden MS; Gillessen S;
Ann Oncol; 2024 Jun; 35(6):485-490. PubMed ID: 38490358
[No Abstract] [Full Text] [Related]
6. Enfortumab vedotin and pembrolizumab combination as a relevant game changer in urothelial carcinoma: What is left behind?
Bellmunt J; Nadal R
Med; 2024 Jun; 5(6):490-492. PubMed ID: 38878766
[TBL] [Abstract][Full Text] [Related]
7. The co-expression of antigen targets as a rationale for ADC combination in urothelial cancer.
Bertucci F; de Nonneville A; Finetti P; Cohendet A; Guille A; Mamessier E
Ann Oncol; 2024 May; 35(5):477-478. PubMed ID: 38364991
[No Abstract] [Full Text] [Related]
8. Re: Erdafitinib or Chemotherapy in Advanced or Metastatic Urothelial Carcinoma.
Tilgener C; Bedke J
Eur Urol; 2024 Jun; 85(6):591-592. PubMed ID: 38538421
[No Abstract] [Full Text] [Related]
9. Is there a role for pembrolizumab beyond progression in urothelial carcinoma?
Taguchi S; Kawai T; Nakagawa T; Kume H
BJU Int; 2024 Jul; 134(1):43-44. PubMed ID: 38073020
[No Abstract] [Full Text] [Related]
10. Management of Oligometastatic and Locally Recurrent Urothelial Carcinoma.
Liu MA; Li JW; Runcie K
Curr Oncol Rep; 2024 May; 26(5):496-503. PubMed ID: 38602581
[TBL] [Abstract][Full Text] [Related]
11. Clinical outcomes in patients with advanced urothelial carcinoma treated with enfortumab vedotin: A retrospective multicenter study in Japan.
Hara T; Matsushita Y; Harada K; Fujimoto N; Fujisawa M; Miyake H
Int J Urol; 2024 Jun; 31(6):696-698. PubMed ID: 38424707
[No Abstract] [Full Text] [Related]
12. Real-world use, dose intensity, and adherence to enfortumab vedotin in locally advanced or metastatic urothelial cancer.
Mamtani R; Tsingas K; Parikh RB; Elsouda D; Mucha L; Fuldeore R; Hubbard RA
Urol Oncol; 2024 Jun; 42(6):177.e1-177.e4. PubMed ID: 38503592
[TBL] [Abstract][Full Text] [Related]
13. Understanding Adjuvant Therapy for Upper Tract Urothelial Carcinoma.
Berg SA; Galsky MD
J Clin Oncol; 2024 May; 42(13):1459-1461. PubMed ID: 38359384
[No Abstract] [Full Text] [Related]
14. Treatment Patterns and Attrition With Lines of Therapy for Advanced Urothelial Carcinoma in the US.
Mathew Thomas V; Jo Y; Tripathi N; Roy S; Chigarira B; Narang A; Gebrael G; Hage Chehade C; Sayegh N; Galarza Fortuna G; Ji R; Campbell P; Li H; Agarwal N; Gupta S; Swami U
JAMA Netw Open; 2024 May; 7(5):e249417. PubMed ID: 38696168
[TBL] [Abstract][Full Text] [Related]
15. Undertreatment in patients with advanced urothelial cancer: systematic literature review and meta-analysis.
Kearney M; Zhang L; Hubscher E; Musat M; Harricharan S; Wilke T
Future Oncol; 2024; 20(16):1123-1137. PubMed ID: 37526215
[No Abstract] [Full Text] [Related]
16. Pathology focused review of morphologic subtypes and molecular variants of urothelial carcinoma with an emphasis on clinical/treatment relevance.
Mahlow J; Gupta S
Urol Oncol; 2024 Jul; 42(7):193-202. PubMed ID: 38341364
[TBL] [Abstract][Full Text] [Related]
17. Lighting the torch: intratumoural T cell-to-stroma enrichment score as a predictor of immunotherapy response in urothelial carcinoma.
Aggen DH; Rosenberg JE
Nat Rev Clin Oncol; 2024 Jul; 21(7):487-488. PubMed ID: 38622410
[No Abstract] [Full Text] [Related]
18. Metastasis-directed therapy among urological malignancies: where do we stand?
Re C; Stewart GD; Capitanio U
Curr Opin Urol; 2024 Jul; 34(4):258-260. PubMed ID: 38835186
[No Abstract] [Full Text] [Related]
19. Editorial Comment to J-AVENUE: A retrospective, real-world study evaluating patient characteristics and outcomes in patients with advanced urothelial carcinoma treated with avelumab first-line maintenance therapy in Japan.
Shindo T
Int J Urol; 2024 May; ():. PubMed ID: 38752600
[No Abstract] [Full Text] [Related]
20. Editorial Comment on "Real-world treatment patterns and quality of life among patients with locally advanced or metastatic urothelial carcinoma living in Saudi Arabia, South Korea, Taiwan, and Turkey".
Giudice GC; Sonpavde GP
Int J Urol; 2024 Jun; ():. PubMed ID: 38825971
[No Abstract] [Full Text] [Related]
[Next] [New Search]
